dc.contributor.author | SAIP, Sabahattin | |
dc.contributor.author | Uygunoglu, Uğur | |
dc.contributor.author | SIVA, Aksel | |
dc.contributor.author | SEYAHI, Emire | |
dc.contributor.author | Zeydan, Burcu | |
dc.contributor.author | DEMIRCI, ON | |
dc.contributor.author | UGURLU, S | |
dc.contributor.author | KANTARCI, OH | |
dc.contributor.author | HAMURYUDAN, Vedat | |
dc.date.accessioned | 2021-03-06T12:48:05Z | |
dc.date.available | 2021-03-06T12:48:05Z | |
dc.identifier.citation | Zeydan B., Uygunoglu U., SAIP S., DEMIRCI O., SEYAHI E., UGURLU S., HAMURYUDAN V., SIVA A., KANTARCI O., "Infliximab is a plausible alternative for neurologic complications of Behçet disease.", Neurology(R) neuroimmunology & neuroinflammation, cilt.3, 2016 | |
dc.identifier.issn | 2332-7812 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_f5a1077d-9608-4ecc-8c00-13de12828aef | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/160975 | |
dc.identifier.uri | https://doi.org/10.1212/nxi.0000000000000258 | |
dc.language.iso | eng | |
dc.title | Infliximab is a plausible alternative for neurologic complications of Behçet disease. | |
dc.type | Makale | |
dc.relation.journal | Neurology(R) neuroimmunology & neuroinflammation | |
dc.contributor.department | Bahçeşehir Üniversitesi , , | |
dc.identifier.volume | 3 | |
dc.contributor.firstauthorID | 177237 | |